Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
PRLD
PRLD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PRLD News
Goldman Sachs Initiates Coverage on Prelude Therapeutics
May 31 2026
Yahoo Finance
Prelude Therapeutics Reports Q1 Earnings and Equity Offering
May 12 2026
seekingalpha
Prelude Therapeutics Prices $90 Million Offering for Oncology Development
Apr 21 2026
NASDAQ.COM
Prelude Therapeutics Prices Public Offering at $4.44 per Share
Apr 20 2026
seekingalpha
Prelude Therapeutics Prices 18 Million Share Offering at $4.44 Each
Apr 20 2026
Newsfilter
Prelude Therapeutics Appoints New Chief Medical Officer
Apr 15 2026
NASDAQ.COM
Prelude Therapeutics Appoints New Chief Medical Officer
Apr 15 2026
Newsfilter
Prelude Therapeutics Reports 2025 Results and Pipeline Update
Mar 11 2026
NASDAQ.COM
Prelude Therapeutics Reports FY Earnings with Revenue Surge
Mar 10 2026
seekingalpha
Prelude Therapeutics Receives FDA Clearance for New Drug Application
Mar 10 2026
Newsfilter
Precision Biologics Market Awakens to $71 Billion Opportunity
Feb 05 2026
Globenewswire
Precision Biologics Market Awakens to $71 Billion Opportunity
Feb 05 2026
Newsfilter
Prelude Therapeutics Receives FDA Clearance for PRT12396 Trials
Feb 03 2026
stocktwits
Prelude Therapeutics Receives FDA Clearance for Blood Cancer Trial
Feb 03 2026
seekingalpha
Prelude Therapeutics Receives FDA Clearance for Phase 1 Study of PRT12396
Feb 03 2026
Newsfilter
Oncolytics Biotech Secures FDA Approval with 33% Efficacy for New Drug
Dec 16 2025
Newsfilter
Show More News
